1	Relationship between plasma cortisol concentration and Long COVID symptoms		
2	in the post-acute phase	of COVID-19: a cross-sectional study and	
3	recommendations for future research		
4 5	Thomas Dalhuisen ¹ , Halle	e Grebe ¹ , Khamal Anglin ¹ , Scott Lu ^{1,2} , Sarah A. Goldberg ^{1,2} ,	
6	Lucas Kallás-Silva ¹ , Joshua Hauser ¹ , Emily Conway ¹ , Marin Ewing ¹ , Jessica Y. Chen ¹ ,		
7	Emily A. Fehrman ¹ , J. Daniel Kelly ² , Jeffrey N. Martin ² , Peter W. Hunt ³ , Timothy J.		
8	Henrich ³ , Matthew S. Durstenfeld ⁴ , Steven G. Deeks ¹ , Elizabeth Murphy ⁵ , Morris		
9	Schambelan⁵, Michael J. Peluso¹		
10			
11	¹ Division of HIV, Infectious Diseases, and Global Medicine, University of California, San		
12	Francisco, San Francisco, CA, USA		
13	² Department of Epidemiology and Biostatistics, University of California, San Francisco,		
14	San Francisco, CA, USA		
15	³ Division of Experimental Medicine, University of California, San Francisco, San		
16	Francisco, CA, USA		
17	⁴ Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA		
18	⁵ Division of Endocrinology, University of California, San Francisco, San Francisco, CA,		
19	USA		
20			
21	Corresponding Author:	Michael Peluso, MD	
22		Division of HIV, Infectious Diseases, and Global Medicine	
23		2540 23 rd St, #4807	
24		San Francisco, CA 94110	
25		michael.peluso@ucsf.edu	
26			
27	Keywords: COVID-19, Long COVID, post-acute sequelae of SARS-CoV-2 (PASC), post-		
28	COVID condition, cortisol		

29 ABSTRACT

BACKGROUND: Low cortisol concentrations have been reported in some people with Long COVID (LC), but more data from diverse cohorts are needed to validate this observation. A subset of people with LC present with symptoms resembling those of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The objective of this study was to compare cortisol concentrations in those with and without Long COVID, with a particular focus on people experiencing ME/CFS-like Long COVID.

36

METHODS: We measured plasma cortisol in 200 individuals 3-6 months following a
SARS-CoV-2 infection. Banked biospecimens collected between 8 AM-12 PM were used.
Participants met the case definition for Long COVID if they had ≥1 COVID-attributed
symptom at least 3 months after symptom onset. People who did not report any symptoms
at least 3 months after symptom onset served as recovered controls. Adapting the 2015
Institute of Medicine criteria for ME/CFS, we further defined those with LC resembling
ME/CFS (LC-ME).

44

RESULTS: We found no difference in overall morning cortisol concentrations between people with LC (n=144) and those who fully recovered (n=56) (median 8.9 μ g/dL vs. 8.8 μ g/dL, p=0.97). Analyses of samples collected between 8-10 AM, however, revealed that, compared to those who fully recovered, cortisol concentrations were lower between 8-9 AM for those with LC-ME (median 8.2 vs. 14.8, p=0.02), but higher between 9-10 AM for those with severe LC (>=5 symptoms) (median 12.4 vs. 8.5, p=0.009) and those with LC-ME (median 13.7 vs. 8.5, p=0.02).

52

53 CONCLUSION: We found no difference in overall morning plasma cortisol concentrations 54 between those with and without Long COVID. Although our data could be suggestive of 55 altered morning cortisol dynamics in a subset of people with Long COVID, longitudinal 56 measures of cortisol in individuals with Long COVID will be critical to further inform the 57 biology of the condition.

58 BACKGROUND

Long COVID is a multisystem condition characterized by a wide range of symptoms that can persist for months or years after SARS-CoV-2 infection¹. The biological mechanisms underlying Long COVID are incompletely understood. Virus persistence, coagulation dysfunction, and inflammation have all been implicated as potential causes^{2,3}.

63

Long COVID is characterized by a variety of different clinical phenotypes and symptom 64 complexes^{2,4}. A subset of people with Long COVID experience fatigue, post-exertional 65 malaise, sleep disturbance, neurocognitive dysfunction, and orthostatic intolerance. 66 67 These symptoms are also characteristic of myalgic encephalomyelitis, sometimes called chronic fatigue syndrome (ME/CFS)⁵. Both Long COVID and ME/CFS are infection-68 associated chronic conditions (IACCs), which are believed by many to be set off by an 69 70 infectious trigger⁶. Determining whether post-COVID ME/CFS represents the same condition as ME/CFS that preceded the COVID-19 pandemic ("pre-pandemic ME/CFS"). 71 and whether they share common biology, remains a key guestion for the field⁷. 72

73

74 SARS-CoV-2 exhibits adrenal tropism, and subsequent adrenal damage and inflammation have been shown in patients with COVID-19⁸. Specifically, SARS-CoV-2 75 76 has been found to replicate in the ACE2 and TMPRSS2 positive cells of the adrenal 77 cortex, resulting in reduced zonation, microthrombi formation, and increased inflammatory infiltrates, which consequently could affect cortisol secretion⁸. Differences 78 79 in systemic cortisol concentrations have been identified in people with Long COVID. suggesting a dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis⁹ in this 80 81 condition. One cross-sectional study, for example, revealed significantly lower cortisol in people with Long COVID compared to healthy controls⁹. In fact, cortisol was the single 82 83 strongest predictor of whether an individual in that study had Long COVID. Other studies, however, have found no evidence for lower cortisol in people with Long COVID^{10,11}. 84 85 Interestingly, studies of pre-pandemic ME/CFS reveal similarly inconsistent results 86 regarding cortisol, with some providing evidence for lower cortisol concentrations and others not^{12,13,14}. A caveat for the interpretation of all of these studies is that cortisol is 87 88 secreted in a pulsatile manner and there is significant diurnal variation with the highest

concentrations in the morning and lowest at night. Thus, the timing of collection may play

- an important role in the interpretation of results. In addition, the secretion of endogenous
- 91 cortisol can be modified by exposure to exogenous glucocorticoids, which are commonly
- 92 used among the population in general and among some individuals with Long COVID.
- 93

To further investigate these questions, we conducted a pilot study to cross-sectionally measure morning plasma cortisol concentrations in a cohort of 200 highly characterized individuals 3-6 months post-COVID. Our objective was to compare cortisol concentrations in those with and without Long COVID with a particular focus on people experiencing ME/CFS-like Long COVID.

99 METHODS

100 Study Design

In this cross-sectional study, we measured plasma cortisol concentrations in participants
 3 to 6 months following symptom onset from a SARS-CoV-2 infection. We included

- 103 participants who had their blood collected between 8 AM and 12 PM.
- 104

105 Participants

Participants were volunteers in the University of California, San Francisco (UCSF)-based Long-term Impact of Infection with Novel Coronavirus (LIINC) research program (NCT04362150)¹⁵. Study procedures have been described in detail previously¹⁵. LIINC enrolls participants with test-confirmed SARS-CoV-2 infection at least two weeks following their symptom onset date. Participants are examined and complete an interviewer-administered symptom questionnaire at an initial study visit and approximately every four months thereafter.

113

114 Case definitions

For these analyses, we defined three groups: a non-Long COVID (nLC) group, a Long 115 116 COVID (LC) group, and a ME/CFS-like Long COVID (LC-ME) group. The nLC group 117 consisted of participants who did not report any COVID-attributed symptoms in the post-118 acute phase and were considered to have fully recovered from their infection. We defined Long COVID according to the World Health Organization consensus criteria¹⁶, as one or 119 120 more COVID-attributed symptom present for more than 3 months following their initial 121 SARS-CoV-2 symptom onset date. We further defined those with Long COVID who met 122 an adaptive version of the 2015 Institute of Medicine ME/CFS criteria⁵ as having LC-ME. 123 These participants reported fatigue, sleep disturbance and neurocognitive dysfunction or 124 orthostatic intolerance. Of note, at the time of this pilot study, a dedicated question 125 regarding post-exertional malaise had not yet been added to the study questionnaire.

126

127 *Measurements*

128 Interviewer-administered questionnaires were used to collect data on Long COVID 129 symptomatology; importantly, symptoms that pre-dated the COVID-19 diagnosis and

- 130 were unchanged were not recorded as representing Long COVID. Cortisol concentrations
- 131 (µg/dL) were measured using previously banked blood samples using the Siemens
- 132 Atellica® IM Analyzer. Cortisol was measured at the UCSF Zuckerberg San Francisco
- 133 General Hospital Clinical Laboratory.
- 134
- 135 Statistical Analyses
- 136 Cortisol concentrations between groups were compared using Wilcoxon rank-sum test.
- 137 We considered a p-value of <0.05 as statistically significant. All analyses were carried out
- 138 with R software version $4.2.2^{17}$.

139 **RESULTS**

140 Study participants

141 We measured cortisol in 200 participants 3 to 6 months following a SARS-CoV-2 infection. Symptom onset date ranged from March 2020 to October 2022. 144 (72%) participants 142 143 met our case definition for Long COVID at the post-acute timepoint. In comparison to the nLC group, the Long COVID group had a similar age (median age 48 vs. 44 years, p=0.5), 144 145 distribution of birth sex (50% vs. 56%, p=0.4) and percentage who had been vaccinated prior to SARS-CoV-2 infection (48 % vs. 51%, p=0.9). A small number of Long COVID 146 participants (3%) reported exogenous glucocorticoid use. Median blood collection time 147 for cortisol measurements was similar for both groups (10:18 AM vs. 10:30 AM). 148 149 Participant characteristics are shown in Table 1.

150

151 Cross-sectional analysis of morning cortisol concentrations

We first compared morning plasma cortisol concentration (μ g/dL) aggregated across all sample collection time points between 8 AM and 12 PM (**Fig. 1A**). We found no difference in median morning cortisol between the LC and nLC group (median 8.9 vs. 8.8, p=0.97).

155 Cortisol concentrations below the lower limit of normal ($<5 \mu g/dL$) were found in 14 (9.7%)

156 LC participants and 5 (8.9%) nLC participants.

157

158 Cross-sectional analysis of cortisol concentrations by hour

159 Given the dynamic nature of cortisol secretion, we next examined cortisol concentrations 160 stratified by hour of collection (Fig. 1B). We observed a non-significant trend for lower cortisol concentrations in those with LC between 8-9 AM (n=19), compared those without 161 162 LC (n=7) (median 12.4 vs.14.8, p=0.36). Between 9-10 AM, however, this relationship 163 reversed, and cortisol concentration tended to be higher in the LC group (n=33) compared to the nLC group (n=12) (median 10.3 vs. 8.5, p=0.15), though again these differences 164 165 were not significant. Cortisol concentrations between 10-11 AM and 11 AM-12 PM were 166 similar in both groups.

- 167
- 168
- 169

170 Cortisol concentrations by symptom count

171 We next stratified the LC group into a severe and non-severe group. Participants in the 172 severe LC group reported 5 or more symptoms (n=60), while participants in the nonsevere LC reported between 1-4 symptoms (n=84) (Fig. 1C). The severe LC group had 173 174 a non-significant trend towards lower cortisol concentration between 8-9 AM (n=9) 175 (median 9.1) compared to the non-severe LC group (n=13) (median 12.0, p=0.52) and 176 the nLC group (n=7) (median 14.8, p=0.44) However, between 9-10 AM, the severe LC 177 group had the highest cortisol concentrations, which differed significantly from the nLC group (median 12.4 vs. 8.5, p=0.009). Cortisol levels were comparable between all groups 178 179 after 10 AM.

180

181 Cortisol concentrations in participants with ME/CFS-like Long COVID

182 Finally, we conducted an exploratory analysis to determine whether the observed differences were driven by the ME/CFS-like phenotype of Long COVID (Fig. 1D). Cortisol 183 concentrations between 8-9 AM were significantly lower in the LC-ME group (n=7) 184 185 compared to the nLC group (n=12) (median 8.2 vs. 14.8, p=0.02). Conversely, cortisol 186 concentrations between 9-10 AM were significantly higher in the LC-ME group (n=3) compared to the nLC group (n=12) (median 13.7 vs. 8.5, p=0.02). This difference was not 187 188 observed when comparing the nLC group with those with LC but without ME/CFS (14.8 vs. 12.6, p=0.78, 8-9 AM; 8.5 vs. 10.2, p=0.27, 9-10 AM). Cortisol levels were comparable 189 190 between all groups after 10 AM.

191 **DISCUSSION**

192 Although we were unable to confirm the broad group differences in morning plasma 193 cortisol concentrations between those with and without Long COVID observed in a prior 194 report⁹, we did make several potentially interesting observations that will inform future 195 work. We found that compared to people who had fully recovered from COVID-19, those 196 with Long COVID tended to exhibit cortisol concentrations that were lower between 8-9 197 AM but higher between 9-10 AM. This pattern appears to be driven by a more symptomatic subset of participants, including those with ME/CFS-like symptoms. Taken 198 199 together, our data are suggestive of altered morning cortisol dynamics in a subset of 200 people with Long COVID. Although the etiology and clinical significance of these findings 201 remains unknown, it suggests a potential physiologic pattern that may distinguish one 202 phenotype of Long COVID and could provide clues as to the pathophysiology driving this 203 debilitating condition.

204

In contrast to a prior report⁹, we failed to detect a difference in cortisol concentration in 205 206 people with Long COVID. This may be explained by differences in cohort characteristics. 207 For example, the median time since acute infection was substantially longer in the prior 208 study than in our cohort (14 months versus 4 months). It could be that this physiologic 209 difference in cortisol concentrations becomes more pronounced over time; this would be 210 consistent with observations in which the disease state and biomarker profiles of ME/CFS, another infection-associated chronic condition, evolves over time¹². Another 211 212 more likely possibility, however, is related to heterogeneity in sampling collection time. 213 Cortisol concentrations fluctuate during the day, typically peaking early in the morning 214 after waking followed by a rapid decline¹⁸. It is possible that inconsistencies in sample timing, even if relatively minor, could drive observable differences if one group is 215 216 measured later than another. In fact the prior report did note differences in sampling time between Long COVID and control groups⁹, although the differences did not reach 217 218 statistical significance.

219

220 Our observation of what may be a different pattern of cortisol secretion in those with 221 ME/CFS-like Long COVID is suggestive of a delayed morning cortisol peak. Although

222 participants in our LC-ME group were not formally diagnosed with ME/CFS, similar 223 examples of alterations in cortisol dynamics can be found the ME/CFS literature^{12,13,19}. 224 For example, one early study measured longitudinal blood cortisol at multiple timepoints 225 throughout the day in patients with ME/CFS and found a reduction in early-morning 226 cortisol¹³. A more recent study found significantly lower salivary cortisol secretion in the 227 morning and flattened cortisol secretion curves at 4 collection times throughout the day 228 among ME/CFS patients compared to healthy controls²⁰. Overall, our findings suggest that further investigation of the patterns of cortisol secretion among those with Long 229 230 COVID, particularly of the ME/CFS-like phenotype, are warranted.

231

232 This study has several limitations. We did not collect information on the time of 233 awakening, therefore analyses could not adjust for waking time. Therefore, these results 234 could be explained by those with ME/CFS having a later waking time and therefore later 235 peak. Our applied case definition of ME/CFS, while consistent with the 2015 IOM criteria, 236 did not accurately capture post-exertional malaise symptoms because this symptom was 237 inconsistently recorded in the first few years of our study; this may have resulted in misclassification of individuals as having ME/CFS-like Long COVID, although such 238 239 misclassification would be expected to make it more difficult to observe an effect. 240 Furthermore, our follow-up interval (3-4 months) represents an earlier timescale than is 241 required for a formal diagnosis of ME/CFS (6 months). We also acknowledge small 242 sample sizes when comparing cortisol concentrations cross-sectionally within the group 243 strata in this exploratory analysis.

244

245 While we believe these observations are intriguing, the main limitation of our study is that 246 these cross-sectional findings do not capture the secretory pattern in any one patient. To 247 better understand cortisol dynamics in Long COVID, future studies should focus on 248 longitudinal measurements of cortisol within individuals. For example, performing serum 249 or salivary collection at short intervals over the course of a day would provide a better 250 assessment of the overall secretory patterns. It is also important that future studies take 251 into consideration the many factors that can have a direct impact on HPA axis activity and 252 cortisol secretion, including glucocorticoid use which is particularly prevalent among those

with this disease condition. It will be vital to take these factors into account to improve study validity and generalizability of results. **Table 2** outlines some considerations we deem important for future studies.

256

Overall, while we could not confirm the dramatic differences in cortisol values observed in prior work, we observed differences in cortisol secretory patterns that suggests that continued efforts to understand pathways related to the HPA axis in Long COVID may be informative. Future efforts will be crucial in eliciting the role of altered cortisol dynamics in individuals with Long COVID and will continue to inform the pathophysiology associated with this condition.

263 FOOTNOTES

264 <u>Acknowledgements</u>

265 We are grateful to the study participants and their medical providers. We acknowledge current LIINC clinical study team members Brent Abel, Grace Anderson, Kofi Asare, 266 267 Tyrine Bailey, Melissa Buitrago, Celina Chang Song, Alexus Clark, Avery Eun, Tony Figueroa, Diana Flores, Yuki Fudotan, Rebecca Hoh, Beatrice Huang, Megan Lew, 268 269 Michael Luna, Kathleen Bellon Pizzaro, Douglas Robbins, Antonio Rodriguez, Dylan 270 Ryder, Viva Tai, Julian Uy, Meghann Williams, and Andhy Zamora; and current LIINC 271 laboratory team members Belen Altamirano-Poblano, Amanda Buck, Lilian Grimbert, and 272 Brian LaFranchi. We thank Pahul Chhabra, Aidan Donovan, Carrie Forman, Rania 273 Ibrahim, Marine Lyden, Sean Thomas, and Badri Viswanathan for assistance with data 274 entry and review. We also acknowledge all former LIINC clinical, laboratory, and data 275 team members. We thank the UCSF AIDS Specimen Bank for processing specimens and maintaining the LIINC biospecimen repository. We are grateful to Elnaz Eilkhani and 276 277 Monika Deswal for regulatory support. We are also grateful for the contributions of 278 additional LIINC leadership team members: Matthew Durstenfeld, Priscilla Hsue, Bryan Greenhouse, Ma Somsouk, Isabelle Rodriguez-Barraguer, and Rachel Rutishauser. 279

280

281 <u>Funding</u>

MJP is supported on K23AI157875. The LIINC clinical core is supported by the PolyBio Research Foundation, with additional funding from R01AI141003 (to TJH) and 1R01NS136197 (to MJP).

285

286 <u>Conflicts of interest</u>

SGD reports consulting for Enanta Pharmaceuticals and Pfizer and reports research support from Aerium Therapeutics outside the submitted work. MJP has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi, outside the submitted work.

REFERENCES

- 1. National Academies of Sciences, Engineering, and Medicine. 2024. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. Washington, DC: The National Academies Press. Https://Doi.Org/10.17226/27768.
- 2. Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell. 2024;187(20):5500-5529. doi:10.1016/j.cell.2024.07.054
- 3. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2
- Kenny G, McCann K, O'Brien C, et al. Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms. Open Forum Infect Dis. 2022;9(4):ofac060. doi:10.1093/ofid/ofac060
- Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/ChronicFatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press (US); 2015. Accessed June 3, 2024. http://www.ncbi.nlm.nih.gov/books/NBK274235/
- 6. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
- Peluso MJ, Hanson MR, Deeks SG. Infection-associated chronic conditions: why long COVID is our best chance to untangle Osler's web. Science Translational Medicine. 2024; In press.
- 8. Paul T, Ledderose S, Bartsch H, et al. Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19. Nat Commun. 2022;13(1):1589. doi:10.1038/s41467-022-29145-3
- Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139-148. doi:10.1038/s41586-023-06651-y
- 10. Appelman B, Charlton BT, Goulding RP, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024;15(1):17. doi:10.1038/s41467-023-44432-3
- Fleischer M, Szepanowski F, Mausberg AK, et al. Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19. Ther Adv Neurol Disord. 2024;17:17562864241229567. doi:10.1177/17562864241229567

- Papadopoulos AS, Cleare AJ. Hypothalamic–pituitary–adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol. 2012;8(1):22-32. doi:10.1038/nrendo.2011.153
- 13. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004;18(4):314-325. doi:10.1016/j.bbi.2003.12.011
- 14. Di Giorgio A, Hudson M, Jerjes W, Cleare AJ. 24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome. Psychosom Med. 2005;67(3):433. doi:10.1097/01.psy.0000161206.55324.8a
- 15. Study Details | Long-term Impact of Infection With Novel Coronavirus (COVID-19) | ClinicalTrials.gov. Accessed June 3, 2024. https://clinicaltrials.gov/study/NCT04362150
- Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9
- 17. Posit team (2023). RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA. URL http://www.posit.com/.
- Adam EK, Hawkley LC, Kudielka BM, Cacioppo JT. Day-to-day dynamics of experience–cortisol associations in a population-based sample of older adults. Proc Natl Acad Sci U S A. 2006;103(45):17058-17063. doi:10.1073/pnas.0605053103
- 19. Nater UM, Youngblood LS, Jones JF, et al. Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome. Psychosom Med. 2008;70(3):298-305. doi:10.1097/PSY.0b013e3181651025
- 20. Chang CJ, Hung LY, Kogelnik AM, et al. A Comprehensive Examination of Severely III ME/CFS Patients. Healthcare. 2021;9(10):1290. doi:10.3390/healthcare9101290
- 21. Granger DA, Hibel LC, Fortunato CK, Kapelewski CH. Medication effects on salivary cortisol: Tactics and strategy to minimize impact in behavioral and developmental science. Psychoneuroendocrinology. 2009;34(10):1437-1448. doi:10.1016/j.psyneuen.2009.06.017
- 22. Wolfram M, Bellingrath S, Kudielka BM. The cortisol awakening response (CAR) across the female menstrual cycle. Psychoneuroendocrinology. 2011;36(6):905-912. doi:10.1016/j.psyneuen.2010.12.006
- 23. Baker FC, Driver HS. Circadian rhythms, sleep, and the menstrual cycle. Sleep Med. 2007;8(6):613-622. doi:10.1016/j.sleep.2006.09.011

- 24. Boivin DB, Boudreau P, Kosmadopoulos A. Disturbance of the Circadian System in Shift Work and Its Health Impact. J Biol Rhythms. 2022;37(1):3-28. doi:10.1177/07487304211064218
- 25. Wang R, Kogler L, Derntl B. Sex differences in cortisol levels in depression: A systematic review and meta-analysis. Front Neuroendocrinol. 2024;72:101118. doi:10.1016/j.yfrne.2023.101118
- 26. Kelestimur F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J Endocrinol Invest. 2004;27(4):380-386. doi:10.1007/BF03351067
- Popescu M, Terzea DC, Carsote M, et al. COVID-19 infection: from stress-related cortisol levels to adrenal glands infarction. Rom J Morphol Embryol. 2022;63(1):39-48. doi:10.47162/RJME.63.1.03
- 28. Parrott AC, Montgomery C, Wetherell MA, Downey LA, Stough C, Scholey AB. MDMA, cortisol, and heightened stress in recreational ecstasy users. Behav Pharmacol. 2014;25(5-6):458-472. doi:10.1097/FBP.00000000000000000
- 29. Stephens MAC, Wand G. Stress and the HPA Axis. Alcohol Res Curr Rev. 2012;34(4):468-483.
- al'Absi M, DeAngelis B, Fiecas M, Budney A, Allen S. Effects of regular cannabis and nicotine use on acute stress responses chronic nicotine, but not cannabis use, is associated with blunted adrenocortical and cardiovascular responses to stress. Psychopharmacology (Berl). 2022;239(5):1551-1561. doi:10.1007/s00213-022-06087-8
- 31. Doane LD, Kremen WS, Eaves LJ, et al. Associations Between Jet Lag and Cortisol Diurnal Rhythms After Domestic Travel. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2010;29(2):117-123. doi:10.1037/a0017865
- 32. Sagmeister MS, Harper L, Hardy RS. Cortisol excess in chronic kidney disease A review of changes and impact on mortality. Front Endocrinol. 2023;13:1075809. doi:10.3389/fendo.2022.1075809
- Tana MM, Alao H, Morris N, et al. Fatigued Patients with Chronic Liver Disease Have Subtle Aberrations of Sleep, Melatonin and Cortisol Circadian Rhythms. Fatigue Biomed Health Behav. 2018;6(1):5-19. doi:10.1080/21641846.2018.1408539
- 34. Ahmed A, Rabbitt E, Brady T, et al. A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease. PLoS ONE. 2012;7(2). doi:10.1371/journal.pone.0029531

- 35. Lovato CM, Thévenot T, Borot S, et al. Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity. JHEP Rep. 2021;3(3). doi:10.1016/j.jhepr.2021.100277
- 36. Dhillo WS, Kong WM, Le Roux CW, et al. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic--pituitary--adrenal axis. Eur J Endocrinol. 2002;146(2):231-235. doi:10.1530/eje.0.1460231

Characteristic	Long Covid (n=144)	No Long Covid (n=56)	Overall (n=200)
Median age, years (IQR)	44 (34 – 56)	48 (38 – 55)	43 (35-56)
Female Birth Sex	81 (56%)	28 (50%)	109 (55%)
Median BMI (IQR)	26 (22 – 31)	25 (22 – 31)	26 (22 – 31)
Race / Ethnicity			
Hispanic/Latino	26 (19%)	9 (16%)	35 (18%)
White	90 (65%)	33 (60%)	123 (62%)
Black/African American	3 (2%)	3 (5%)	6 (3%)
Asian	17 (12%)	9 (16%)	26 (13%)
Pacific Islander/Native Hawaiian	1 (1%)	1 (2%)	2 (1%)
American Indian or Alaska Native	2 (2%)	0 (0%)	2 (1%)
Unknown/Declined	5 (4%)	1 (1%)	6 (3%)
Hospitalized	14 (10%)	6 (11%)	20 (10%)
HIV Seropositive	20 (14%)	10 (18%)	30 (15%)
Vaccinated at time of symptom onset	74 (51%)	27(48%)	101 (51%)
Median number of days post symptom onset (IQR)	122 (113-134)	123 (115 – 131)	123 (113 – 133)
Median collection time* (IQR)	10:30 AM	10:18 AM	10:28 AM
· · ·	(9:30 AM –	(9:20 AM –	(9:28 AM –
	11:09 AM)	10:58 AM)	11:05 AM)
Symptom count (IQR)	4 (2-8)	0 (0-0)	2 (0 – 6)

 Table 1. Characteristics of study participants.

IQR = interquartile range. *Collection time of blood sample used to measure plasma cortisol concentrations.

Table 2. Proposed approaches or considerations for studies evaluating cortisol secretion dynamics.

Confounding Variable	Proposed Approach or Considerations
Medications	Obtain a full medication list and carefully document participants' medications, especially those which may alter cortisol secretion (e.g., glucocorticoids, levothyroxine, etc.) ²¹ . Obtain full medication list, as many participants may not be aware that a medication they are taking is a glucocorticoid. Consider exclusions based on current or recent use.
Phase in menstrual cycle	If applicable, record the participant's menstrual cycle phase. Some data suggest cortisol awakening response levels increase during ovulation ²² and an increased glucocorticoid ²³ response in the luteal phase.
Sleep cycle disturbances	Record participants' usual sleep patterns. Abnormal sleep patterns, like those often associated with shift work, alter the body's circadian rhythms and may affect the timing of cortisol secretion ²⁴ .
Mental health	Carefully document participants' mental health comorbidities. Individuals with depression have been shown to have a hyperactive HPA axis ²⁵ .
Intercurrent infections	Screen for and document any recent or intercurrent infections. Cortisol secretion may be altered in chronic ²⁶ and acute infections, including COVID-19 ²⁷ .
Substance use history	Document recent history of substance use. Alcohol, nicotine and other drugs have been implicated in dysregulation of cortisol secretion ^{28,29,30} .
Recent travel across time zones	Exclude participants who have recently traveled across time zones ³¹ .
Comorbidities	Document history of liver or kidney disease, which may directly impact cortisol secretion and/or metabolism ^{32,33,34,35} .
Abnormal cortisol binding globulin (CBG)	Consider testing samples for differences in quantity of CBG, which may vary significantly between individuals ³⁶ .



Figure 1. **A.** Morning cortisol concentration (μ g/dL) in participants with Long COVID compared to those without. **B.** Cortisol concentrations stratified by hourly time bin. **C.** Cortisol concentrations stratified by symptom count and hourly time bin. Statistically significant group comparisons are indicated. **D.** Cortisol concentrations in LC-ME compared to those without stratified by hourly time bin. Statistically significant group comparisons are indicated. **D.** Cortisol concentrations in LC-ME compared to those without stratified by hourly time bin. Statistically significant group comparisons are indicated. Abbreviations: LC = Long COVID; nLC = non-Long COVID (e.g., post-COVID but fully recovered); LC-ME = ME/CFS-like Long COVID according to the adapted 2015 Institute of Medicine criteria.